Cryo-Cell International Inc. (CCEL)
| Market Cap | 67.84M |
| Revenue (ttm) | 30.39M |
| Net Income (ttm) | 3.63M |
| Shares Out | 7.57M |
| EPS (ttm) | 0.45 |
| PE Ratio | 18.89 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 6 |
| Last Price | $8.50 |
| Previous Close | $8.50 |
| Change ($) | 0.00 |
| Change (%) | -0.03% |
| Day's Open | 8.55 |
| Day's Range | 8.50 - 8.60 |
| Day's Volume | 8,239 |
| 52-Week Range | 6.31 - 10.10 |
News
OLDSMAR, Fla., April 14, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem ...
About CCEL
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, kidney, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to p... [Read more...]
| Industry Medical Care Facilities | IPO Date Jan 21, 1997 |
| Stock Exchange OTCMKTS | Ticker Symbol CCEL |
Financial Performance
In 2020, CCEL's revenue was $31.15 million, a decrease of -2.10% compared to the previous year's $31.82 million. Earnings were $3.62 million, an increase of 58.23%.